+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06970639

Phase III Study Comparing Furmonertinib Plus Platinum-Based Chemotherapy Versus Osimertinib in Patients With EGFR Mutation-Positive Non-Squamous NSCLC and Brain Metastases

Led by Allist Pharmaceuticals, Inc. · Updated on 2026-08-13

380

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase III international clinical trial to assess the safety and effectiveness of furmonertinib combined with platinum-based doublet chemotherapy versus osimertinib alone in patients with non-squamous non-small cell lung cancer NSCLC that has an EGFR sensitizing mutation and brain metastases. The study also includes a group receiving furmonertinib alone to further explore its effects. This trial aims to understand better treatment options for this specific lung cancer subgroup. The study has two stages. The first stage focuses on safety and involves about 30 participants receiving either 80 mg or 160 mg of furmonertinib daily combined with chemotherapy to evaluate tolerability. The second stage randomizes around 350 participants into three groups furmonertinib with chemotherapy, osimertinib alone, or furmonertinib alone. Treatments are given in cycles of 21 days and continue until unacceptable side effects, disease progression, death, or new treatment begins. Chemotherapy includes drugs like carboplatin, cisplatin, and pemetrexed administered intravenously every three weeks for up to four cycles. Participants will undergo regular assessments including monitoring of side effects, disease progression, and survival for up to four years. Researchers will use imaging and clinical evaluations to measure outcomes such as progression-free survival and response rates. Patient-reported outcomes and various blood tests will also be collected. Safety monitoring involves tracking adverse events and serious adverse events throughout the study duration. The total study period extends until September 2029, with detailed follow-up to observe long-term effects and treatment impact.

CONDITIONS

Brief Title

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Research Team

S

Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here